Illumina, Inc. (FRA:ILU)

Germany flag Germany · Delayed Price · Currency is EUR
78.33
+1.43 (1.86%)
At close: Jun 20, 2025, 10:00 PM CET
-23.34%
Market Cap 12.74B
Revenue (ttm) 4.00B
Net Income (ttm) -891.81M
Shares Out n/a
EPS (ttm) -5.61
PE Ratio n/a
Forward PE 21.85
Dividend n/a
Ex-Dividend Date n/a
Volume 20
Average Volume 52
Open 78.27
Previous Close 76.90
Day's Range 78.27 - 78.33
52-Week Range 62.29 - 146.32
Beta n/a
RSI 63.71
Earnings Date Aug 7, 2025

About Illumina

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole... [Read more]

Industry Laboratory Analytical Instruments
Founded 1998
Employees 9,030
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol ILU
Full Company Profile

Financial Performance

In 2024, Illumina's revenue was $4.37 billion, a decrease of -2.93% compared to the previous year's $4.50 billion. Losses were -$1.22 billion, 5.34% more than in 2023.

Financial numbers in USD Financial Statements

News

Dr. Lal PathLabs boots genomics capabilities with Illumina’s NovaSeq™ X Series

Dr. Lal PathLabs Limited (DLPL), one of India’s most trusted names in diagnostics, has taken a major step forward in genomics by adding the advanced NovaSeq™ X Series from Illumina to its dedicated ge...

2 days ago - Business Upturn

SomaLogic Acquisition Marks Next Step In Illumina's Advanced Biomarker Push

Illumina will acquire SomaLogic to expand ... Full story available on Benzinga.com

3 days ago - Benzinga

Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy

Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market Illumin...

3 days ago - PRNewsWire

Infinity Bio Closes $8M Series A Financing Led by Illumina Ventures to Expand Leadership in Antibody Reactome Profiling

BALTIMORE--(BUSINESS WIRE)--Infinity Bio, a biotechnology company pioneering technologies to map immune responses at scale, today announced the successful closing of an $8 million Series A financing r...

8 days ago - Business Wire

lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics

SAN DIEGO , June 10, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), aligned with its commitments to advance the power of genomics, today published its annual Corporate Social Responsibility (CSR) ...

16 days ago - PRNewsWire

Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis

New AI algorithm accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome at scale for the first time SAN DIEGO , May 29, 2025 /PRNewswire/ -- Illumina ...

4 weeks ago - PRNewsWire

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see...

4 weeks ago - CNBC Television

Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies

Following FDA approval last year, Illumina's TSO Comprehensive test gains broad payer reimbursement, expanding access to comprehensive genomic profiling to match patients with targeted therapies Illum...

4 weeks ago - PRNewsWire

Signios Bio and Illumina Announce Grant to Maximize Discovery Power with Industry's Largest NGS-Based Proteomics Panel

FOSTER CITY, Calif.--(BUSINESS WIRE)--Signios Biosciences (“Signios Bio”), a science-first biotechnology company leading in multiomics and AI-powered bioinformatics, in collaboration with Illumina, an...

5 weeks ago - Business Wire

Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90%

Carl Icahn is making bold moves from the lab to the tarmac.

5 weeks ago - Benzinga

Quantum-Si (QSI) Earnings Coverage: Complete 1Q Coverage

Live Updates Live Coverage Updates appear automatically as they are published. QSI Earnings Backdrop 11:26 am Quantum-Si operates at the intersection of biotech instrumentation and proteomics, targeti...

6 weeks ago - 24/7 Wall street

Illumina To Webcast Upcoming Investor Conference

SAN DIEGO , May 14, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: 41st Annual Bernstein Strategic Decisi...

6 weeks ago - PRNewsWire

Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications

Building on reputation for unparalleled performance, latest software delivers even greater accuracy, with 30% improvement in structural variant calling New features include easy-to-use oncology apps, ...

6 weeks ago - PRNewsWire

Illumina Analysts Lower Their Forecasts After Q1 Results

Illumina, Inc. (NASDAQ: ILMN) reported upbeat earnings for the first quarter, but lowered its FY25 guidance, after the closing bell on Thursday. The company posted quarterly earnings of 97 cents per ...

6 weeks ago - Benzinga

Illumina Analysts Lower Their Forecasts After Q1 Results

Illumina, Inc. ILMN reported upbeat earnings for the first quarter, but lowered its FY25 guidance, after the closing bell on Thursday.

6 weeks ago - Benzinga

Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development

First real-world dataset with integrated clinical and multiomic insights from 25,000 patients treated with GLP-1 therapies Dataset will advance development of GLP-1 therapies in new indications and ac...

2 months ago - PRNewsWire

Rep. Thomas Kean Has Bought Up to $45K Worth Of Illumina Stock: Here's What You Should Know

April 18, 2025 records indicate that Representative Thomas Kean filed a purchase of Illumina (NASDAQ: ILMN), valued between $3,003 and $45,000. According to the April filing, the transaction occurred...

2 months ago - Benzinga